Recently Added Drugs

1. Drug name - ANJESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458145 BAUDAX Methods of administering intravenous meloxicam in a bolus dose
Mar, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446318 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

3. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
New Chemical Entity Exclusivity (NCE) Apr 3, 2022
M Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

4. Drug name - CERDELGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(7 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

5. Drug name - DEXTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4MG INSERT;OPHTHALMIC Prescription

6. Drug name - DROSPIRENONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478487 EXELTIS USA INC
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
3.5MG TABLET, CHEWABLE;ORAL Prescription

7. Drug name - EMERPHED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464752 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 17 April, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/10ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

8. Drug name - FERRIPROX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Apr 30, 2024

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 19 May, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET;ORAL Prescription

9. Drug name - FUROSCIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433044 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(11 years from now)

US9884039 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(11 years from now)

US10272064 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(11 years from now)

Drugs and Companies using FUROSEMIDE ingredient

Market Authorisation Date: 07 October, 2022

Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
80MG/10ML (8MG/ML) SOLUTION;SUBCUTANEOUS Prescription

10. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458128 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

11. Drug name - IHEEZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792271 SINTETICA SA Topical formulations of chloroprocaine and methods of using same
Sep, 2038

(15 years from now)

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2022

Treatment: Method of inducing ocular anesthesia

Dosage: GEL;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
3% GEL;OPHTHALMIC Prescription

12. Drug name - KATERZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11471409 AZURITY
Oct, 2037

(14 years from now)

US11484498 AZURITY
Oct, 2037

(14 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: A method of treating coronary artery disease; A method of treating hypertension

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML SUSPENSION;ORAL Prescription

13. Drug name - KONVOMEP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751333 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(16 years from now)

US11103492 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(16 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
2MG/ML;84MG/ML FOR SUSPENSION;ORAL Prescription

14. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47954 ONYX THERAP Combination therapy with peptide epoxyketones
Oct, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

Market Authorisation Date: 20 July, 2012

Treatment: Use in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

15. Drug name - LYTGOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(10 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027

Drugs and Companies using FUTIBATINIB ingredient

Market Authorisation Date: 30 September, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
4MG TABLET;ORAL Prescription

16. Drug name - MAKENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446441 COVIS Prefilled syringe injector
Jan, 2026

(3 years from now)

US11446440 COVIS Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1250MG/5ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
250MG/ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
275MG/1.1ML (250MG/ML) SOLUTION;SUBCUTANEOUS Prescription

17. Drug name - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11413259 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(15 years from now)

US10420735 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(15 years from now)

US10226436 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(15 years from now)

US10159657 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(15 years from now)

US10568850 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(15 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 06 October, 2022

Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription

18. Drug name - OMLONTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648097 SANTEN Pyridylaminoacetic acid compound
Oct, 2029

(6 years from now)

US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 SANTEN Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(6 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(12 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(12 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(12 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(12 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(12 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.002% SOLUTION;OPHTHALMIC Prescription

19. Drug name - OTREXUP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446441 OTTER PHARMS Prefilled syringe injector
Jan, 2026

(3 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 11 October, 2013

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.4ML (7.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
10MG/0.4ML (10MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
12.5MG/0.4ML (12.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.4ML (15MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.4ML (17.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.4ML (22.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.4ML (25MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.6ML (15MG/0.6ML) SOLUTION;SUBCUTANEOUS Discontinued
17.5MG/0.7ML (17.5MG/0.7ML) SOLUTION;SUBCUTANEOUS Discontinued
20MG/0.8ML (20MG/0.8ML) SOLUTION;SUBCUTANEOUS Discontinued
22.5MG/0.9ML (22.5MG/0.9ML) SOLUTION;SUBCUTANEOUS Discontinued
25MG/ML (25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

20. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

Market Authorisation Date: 17 December, 2021

Treatment: Treating sickle cell disease by administering voxelotor and another active agent

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, FOR SUSPENSION;ORAL Prescription

21. Drug name - OXLUMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 23, 2027
New Chemical Entity Exclusivity (NCE) Nov 23, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

Market Authorisation Date: 23 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

22. Drug name - PEDMARK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190 FENNEC PHARMS INC Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
Jan, 2038

(15 years from now)

US11291728 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(16 years from now)

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
12.5GM/100ML (125MG/ML) SOLUTION;INTRAVENOUS Prescription

23. Drug name - PEMAZYRE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
4.5MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
13.5MG TABLET;ORAL Prescription

24. Drug name - RECORLEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478471 STRONGBRIDGE
Jan, 2026

(3 years from now)

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

25. Drug name - RELYVRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(11 years from now)

US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(11 years from now)

US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(11 years from now)

US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2027

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
3GM/PACKET; 1GM/PACKET FOR SUSPENSION;ORAL Prescription

26. Drug name - SEGLENTIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478488 KOWA PHARMS
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 15, 2024

Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: A method for treatment of pain in adults using tramadol hydrochloride and celecoxib

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
56MG;44MG TABLET;ORAL Prescription

27. Drug name - SLYND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478487 EXELTIS USA INC
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 23, 2022

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 23 May, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
4MG TABLET;ORAL Prescription

28. Drug name - SPRAVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 5, 2024
New Indication (I) Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 28MG BASE SPRAY;NASAL Prescription

29. Drug name - SUNOSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

30. Drug name - TRIKAFTA (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11453655 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(15 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 8, 2024
New Chemical Entity Exclusivity (NCE) Oct 21, 2024
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

Market Authorisation Date: 21 October, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG,37.5MG,25MG; 75MG TABLET;ORAL Prescription
100MG,75MG,50MG; 150MG TABLET;ORAL Prescription

31. Drug name - TRINTELLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458134 TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jan 22, 2024

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Market Authorisation Date: 30 September, 2013

Treatment: Use of trintellix for the treatment of major depressive disorder (mdd) in adults

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Prescription

32. Drug name - YUPELRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11484531 MYLAN IRELAND LTD
Oct, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 9, 2023

Drugs and Companies using REVEFENACIN ingredient

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
175MCG/3ML SOLUTION;INHALATION Prescription

33. Drug name - ZONISADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478456 AZURITY
Aug, 2038

(15 years from now)

Drugs and Companies using ZONISAMIDE ingredient

Market Authorisation Date: 15 July, 2022

Treatment: A method of treating seizures

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/5ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in